GSK shares up 3% as sales and earnings exceed expectations

27 April 2022
glaxosmithkline_gsk_large

UK drugmaker GlaxoSmithKline (LSE: GSK) has impressed investors with its first quarter 2022 financial results, with its share price closing 3% higher on Wednesday.

GSK is in an important year, with plans to split off its Consumer Healthcare unit in July, and many eyes on the progress of its Biopharma business as it prepares to go it alone.

'Good momentum across specialty medicines and vaccines'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical